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Bifidobacterium bifidum PRL2010 Modulates the Host Innate Immune
Response
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Laura Gioiosa,e Paola Palanza,e Abelardo Margolles,c Douwe van Sinderen,a Marco Venturac
‹Alimentary Pharmabiotic Centre and Department of Microbiology, Bioscience Institute, National University of Ireland, Cork, Irelanda; Dipartimento di Scienze e Tecnologie
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Asturias, Spainc; Laboratory of Probiogenomics, Department of Life Sciences, University of Parma, Parma, Italyd; Department of Evolutionary and Functional Biology,
University of Parma, Parma, Italye
Here, we describe data obtained from transcriptome profiling of human cell lines and intestinal cells of a murine model upon
exposure and colonization, respectively, with Bifidobacterium bifidum PRL2010. Significant changes were detected in the tran-
scription of genes that are known to be involved in innate immunity. Furthermore, results from enzyme-linked immunosorbent
assays (ELISAs) showed that exposure to B. bifidum PRL2010 causes enhanced production of interleukin 6 (IL-6) and IL-8 cyto-
kines, presumably through NF-B activation. The obtained global transcription profiles strongly suggest that Bifidobacterium
bifidum PRL2010 modulates the innate immune response of the host.
During the last decade, bifidobacteria have attracted a lot ofscientific attention due to their perceived role as health-pro-
moting or probiotic bacteria. Although there is suggestive proof to
corroborate some of these functional claims, themolecularmech-
anisms behind such probiotic activities remain largely unknown.
The decoding and functional analysis of genome sequences of pro-
biotic bacteria, i.e., probiogenomics, offer the possibility of accel-
erating research into the mechanisms of probiotic action (1, 2).
Probiogenomic investigations have highlighted a plethora of ge-
netic features that may explain how bifidobacteria have so well
adapted to the human gut. Prominent examples are represented
by the genes and their products that allow bifidobacteria to inter-
act with the human host, either through different morphological
structures, such as pili (3, 4) or exopolysaccharides (5), or through
the utilization of host-derived glycans, such as mucin or human
milk oligosaccharides (6, 7). Nevertheless, so far, relatively little is
known about the changes that occur in the host’s transcriptome in
response to bifidobacterial colonization/exposure (8, 9). Among
the various human bifidobacteria, a special mention should be
reserved for Bifidobacterium bifidum PRL2010, whose genome has
been subjected to sequencing and functional analysis, which has
revealed a number of key traits that render this bacterium amodel
organism for the investigation of human-microbe coevolution (6,
10, 11). These analyses of B. bifidum PRL2010 have provided in-
sights that explain not only the genomic strategy adopted by this
strain to metabolize host-derived glycans (6, 10) but also the pro-
cess of host colonization through sortase-dependent pili (12).
B. bifidum strains are claimed to exert a key role in the evolu-
tion and maturation of the immune system of the host, which is
still rather undeveloped following birth (9). The interaction of B.
bifidum with the host immune system has recently been explored
by analyzing the impact of B. bifidum Z9 in combination with a
second human gut commensal, Lactobacillus acidophilus, on the
transcriptome of dendritic cells (DCs) (8). This study revealed
that B. bifidumZ9 inhibits expression of genes related to the adap-
tive immune system in murine dendritic cells. These findings are
in line with those of other publications that employed in vitro
assays involving various bifidobacterial strains belonging to dif-
ferent species, showing a clear and distinct cytokine profile in-
duced by bifidobacteria (9, 13).
The purpose of the current study was to investigate the partic-
ular host gene expression profile following exposure to and/or
colonization with B. bifidum PRL2010 by employing microarray-
based transcriptome analyses coupled with in vitro (colonic cell
line) and in vivo (murine-colonization) approaches.
MATERIALS AND METHODS
Growth conditions. B. bifidum PRL2010 was cultivated in an anaerobic
atmosphere (2.99% H2, 17.01% CO2, and 80% N2) in a chamber (Con-
cept 400; Ruskin) at 37°C for 32 h in de Man-Rogosa-Sharpe (MRS;
Scharlau Chemie, Barcelona, Spain) medium, supplemented with 0.05%
(wt/vol) L-cysteine hydrochloride.
Stimulation of Caco-2 monolayers and ELISA measurement of cy-
tokine production. A predetermined number of Caco-2 cells was seeded
into 24-well plates and grown as described previously (14). B. bifidum
PRL2010 cells (final concentration of 108 bacterial cells ml1) were added
tomonolayers of Caco-2 cells at amultiplicity of infection (MOI) of 100 in
0.5 ml of fresh antibiotic-free Dulbecco’s modified Eagle’s medium
(DMEM) and incubated for 18 h at 37°C in 5% CO2. This timing was
optimized as described previously (14). The cytokine interleukin 1 (IL-
1) (1 ng/ml), casein (10 g/ml), and bovine serum albumin (BSA) (10
g/ml) were used as controls.Microtiter plates were kept at70°C for 4 h
to completely disrupt the Caco-2 cells. The supernatant and disrupted
Caco-2 cells were then collected, and phenylmethylsulfonyl fluoride (20
mM final concentration) was added. After centrifugation at a relative
centrifugal force of 16,000  g for 1 min, levels of IL-2, IL-4, IL-6, IL-8,
IL-10, gamma interferon (IFN-), and tumor necrosis factor alpha
(TNF-) in the supernatants were determined by enzyme-linked immu-
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nosorbent assay (ELISA) using Bio-Plex human cytokine multiplex panel
(Bio-Rad Laboratories, Segrate, Italy) as instructed by the manufacturer.
Each sample was processed in duplicate in two independent experiments.
Evaluation of NF-B activation. A stable recombinant Caco-2 cell
line was obtained by transfecting cells with the plasmid pNiFty2-Luc
(InvivoGen, Labogen, Rho, Italy) as described previously (15). This plasmid
combines five nuclear factor B (NF-B)-dependent transcriptional acti-
vation sites upstream of the insect luciferase reporter gene luc. The pres-
ence of active NF-B molecules in the cell activates the promoter, result-
ing in expression of the luciferase gene. Following growth in the presence
of 50 g/ml zeocin, cell monolayers (approximately 3  105 cells/well)
were carefully washedwith 0.1MTris-HCl buffer (pH 8.0). Subsequently,
50l of a bacterial suspension containing 2.5 108 cells was added to 0.45
ml of fresh DMEM containing 100 mM HEPES (pH 7.4). The resulting
500 l was finally pipetted into the microtiter plate well containing the
Caco-2 cell layer, resulting in an MOI of 100. Stimulation was conducted
both in the presence and the absence of 2 ng/ml of IL-1. After incubation
at 37°C for 4 h, the samples were treated and the bioluminescence was
measured as described previously (16). All conditions were analyzed in
triplicate in at least two independent experiments.
Tissue culture experiments. About 2  105 HT29 cells in 1.5 ml of
DMEM (high glucose, HEPES) medium supplemented with 10% heat-
inactivated fetal bovine serum (Life Technologies, Italy), penicillin (100
U/ml), streptomycin (0.1 mg/ml), amphotericin B (0.25 g/ml), and 4
mM L-glutamine were seeded into the upper compartments of a six-well
transwell plate. The lower compartments contained 3.0 ml of the same
medium. HT29 cells were incubated at 37°C in a 5% CO2 atmosphere
until they reached 3 days postconfluence. Cells were then washed with
Hank’s solution and stepped down in DMEM supplemented with L-glu-
tamine (4 mM), sodium selenite (0.2 g/ml), and transferrin (5 g/ml)
for 24 h. These transwell inserts were transferred to an anaerobic culture
box within an MACS-MG-1000 anaerobic workstation at 37°C, and each
insert was filled with anaerobic DMEM. A culture of B. bifidum PRL2010
grown to exponential phase was harvested by centrifugation at 3,500 g
for 5min andwashedwith 10ml of anaerobicDMEM.The obtained pellet
was resuspended in 0.8 ml of the samemedium. One hundredmicroliters
of bacterial suspension (108 CFU/ml) was added to wells, with control
wells receiving the same amount of medium without bacterial cells. An
additional control included bacterial cells incubated without HT29 cells.
Tissue culture cells were harvested for analyses after 1 h, 2 h, and 4 h of
incubation (with bacterial cultures) and 1 h (unexposed cell control
placed in contact with phosphate-buffered saline [PBS] for 1 h) for time
course-dependent gene expression studies. This study design is similar to
those employed in two previous studies, one involving B. bifidum
PRL2010 and a Caco-2 human cell monolayer (6) and the second involv-
ing human gut commensal bacteria and human epithelial cells (17). Non-
adherent bacteria were carefully aspirated from the wells and pooled,
while the adherent fraction was collected after washing of the inserts with
anaerobic media and also pooled. Each fraction was collected into 1.5-ml
tubes and centrifuged at 3,500  g for 5 min, and the resulting pellet
resuspended in 400 l of RNAlater and subjected to RNA extraction ac-
cording to the protocol described below. Caco-2 cells or HT29 cells were
harvested from the wells, pooled, and stored in RNAlater at 4°C.
Mouse colonization. All procedures were approved by the University
of Parma, as represented by the Institutional Animal Care and Use Com-
mittee (Dipartimento per la Sanità Pubblica Veterinaria, laNutrizione e la
Sicurezza degli Alimenti Direzione Generale della Sanità Animale e del
Farmaco Veterinario). Two groups of mice were orally inoculated with
either 109 CFU of PRL2010 cells (test strain) or water (control), according
to previously described protocols (12, 18). Each group contained five
animals of 3-month-old female BALB/c mice. Bacterial colonization was
established by five consecutive daily administrations, during which each
animal received 20 l of 109 cells using a micropipette tip placed imme-
diately behind the incisors (19). Bifidobacterial inocula were prepared as
described previously (18).
In order to estimate the number of B. bifidum PRL2010 cells per gram
of feces, individual fecal samples were serially diluted and cultured on
selective agar (MRS agar) using mupirocin as described previously (20).
Following enumeration of B. bifidum PRL2010 cells in fecal samples, 100
random colonies were further tested to verify their identity using PCR
primers targeting the pil-2 and pil-3 loci (3).
Animals were sacrificed by cervical dislocation, and individual gastro-
intestinal tracts were removed and used for RNA extraction.
Eukaryotic RNA isolation.Human cell lines as well as cells frommu-
rine gastrointestinal tracts in RNAlater were diluted 1:1 in an equal vol-
ume of sterile PBS, followed by centrifugation at 5,000 g for 10 min at
4°C. Total RNA from the pellet was isolated using the RNeasy minikit
(Qiagen, Italy) according to themanufacturer’s instructions, including an
RNase-free DNase I (Qiagen, Italy) digestion step. Eukaryotic RNA integ-
rity was determined using the Experion automated electrophoresis system
(Bio-Rad, Italy).
Acceptable RNA purity values (optical density at 260 nm [OD260]/
OD280) had to be 1.8, with corresponding RNA integrity numbers
(RIN) ranging from 7 to 9.
Microarray, description, labeling, and hybridizations. Microarray
analysis was performedwith an oligonucleotide array based on the human
genome as well as the murine genome from CombiMatrix. Oligonucleo-
tides were present in triplicate on a 90k CombiMatrix array (Combi-
Matrix, Mukilteo,WA,USA). Replicates were distributed on the chip at ran-
dom, nonadjacent positions. A set of 74 negative-control probes designed on
the basis of phage and plant sequences were also included on the chip.
Reverse transcription (RT) and amplification of 500 ng of total RNA
was performedwith ImProm-II reverse transcriptase (Promega,Madison,
USA) according to the manufacturer’s instructions. Five micrograms of
cDNA was then labeled with a ULS labeling kit for CombiMatrix arrays
with Cy5 (Kreatech, The Netherlands). Hybridizations were performed
according to a previously described protocol (21).
Microarray data acquisition and treatment. Fluorescence scanning
was performed on an InnoScan 710 microarray scanner (Innopsys,
France). Signal intensities for each spot were determined using GenePix
Pro 7 software (Molecular Devices, USA). Signal background was calcu-
lated as the mean of results for negative controls plus 2 times the standard
deviation (22). A global quantile normalization analysis was performed
(23), and log2 ratios between the reference sample and the test sample
results were calculated. The distribution of the log2-transformed ratios
was separately calculated for each hybridization reaction. The fold change
cutoff value for transcriptomic data analyses was 2 for upregulated
genes and 0.5 for downregulated genes. Only those genes whose tran-
scription levels were shown to be significantly different (24) were further
taken into consideration in our analyses.
Statistical analysis. Statistical significance between means was ana-
lyzed using the unpaired Student t test, with a threshold P value of
	0.0005. Values are expressed as the means
 the standard errors of the
means of results from three experiments. Statistical calculations were
performed using the software program GraphPad (La Jolla, CA, USA)
Prism 5.
Microarray accession number. The transcriptional array data have
been deposited in the GEO database under accession number GSE48533.
RESULTS AND DISCUSSION
Modulation of cytokine gene expression by PRL2010 in Caco-2
cells is mediated by NF-B activation. Caco-2 cells are human
colonic adenocarcinoma cells that are able to express differentia-
tion features typical of mature intestinal cells and that, conse-
quently, are one of the most commonly employed cell lines for in
vitro studies related to intestinal cell function and differentiation
(25). In a previous study, we demonstrated that, using this Caco-2
in vitro model, B. bifidum PRL2010 can modulate the expression
of genes encoding certain interleukins and cytokine transcrip-
tional regulators (6). Specifically, 4-h incubation of PRL2010 with
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Caco-2 cells was shown to cause a significant rise in the transcrip-
tion (4.19-fold; P	 0.0005) of the genes for the nuclear factor B
(NF-B) p105 subunit (NFKB1) and interleukin 8 (IL-8) (6). Par-
ticularly, the increased transcription of NFKB1 is expected to
cause enhanced activation of the transcriptional regulator NF-B,
which is a well-known transcriptional inducer of IL-8, thus ex-
plaining its observed enhanced transcription, as well as of other
cytokines. To experimentally confirm this notion, we quantified
several cytokines in the broth culture of Caco-2 cells by ELISA
analysis. Differentiated Caco-2 layers were prepared as previously
described (14) and stimulated with B. bifidum PRL2010 cells for
18 h at a bifidobacterial-cell/Caco-2-cell ratio of 100. The results
clearly show that strain PRL2010 induced an 11-fold (P	 0.001)
and a 4-fold (P 	 0.001) increase in secreted IL-6 and IL-8, re-
spectively (Fig. 1a), while broth concentrations of IL-2, IL-4, IL-
10, IFN-, and TNF- were not significantly above the detection
limit (Fig. 1a). The ability to directly stimulate secretion of similar
cytokines by Caco-2 cells has not received much attention. For
instance, B. bifidum MIMBb75 has been reported to trigger IL-8
production, whereas IL-6 was shown to be unaffected (14). In
contrast, the enhanced simultaneous stimulation of IL-6 and IL-8
was reported for other bifidobacterial species, such as B. breve
(26).
To further explore the immune-modulatory properties of
PRL2010, we tested the effect of this bifidobacterial strain on
NF-B activation using a recombinant cell line, obtained by trans-
fectingCaco-2 cells with a vector containing anNF-B-dependent
luciferase reporter (15). In this model, 4-h incubation with strain
PRL2010 showed a stimulatory effect on NF-B-dependent pro-
duction of bioluminescence (81%) (Fig. 1b). The increase of
NF-B activation was also evident for strain PRL2010 when
Caco-2 cells were incubated with bacteria and IL-1, which has
been used as a proinflammatory stimulus. These results demon-
strate thatB. bifidumPRL2010 can activelymodulate epithelial cell
responses at a transcriptional level. A similar scenario has previ-
ously been noticed for a number of other bacteria, which were
shown to either increase (in the case of Streptococcus salivarius ST3
[27]) or decrease (in the case of Lactobacillus helveticus MIMLh5
[15]) NF-B activation in epithelial cells. Further examples con-
cerning bifidobacteria are available in the literature; secreted fac-
tors from Bifidobacterium animalis subsp. lactis were shown to
inhibitNF-B-mediated IL-8 gene expression inCaco-2 cells (28),
while increased NF-B expression in Caco-2 cells was observed
upon stimulation with B. breve DSMZ 20091-conditioned media
(29). Therefore, modulation of the NF-B signal transduction
pathway can be considered a general mechanism of cross talk be-
tween host epithelial cells and various (commensal and/or probi-
otic) microorganisms. In addition, the observed ability of B. bifi-
dum PRL2010 to induce chemokine production of IL-8 by
intestinal epithelial cells may contribute to the enhancement of
the innate immune response.
Modulation of HT29 gene expression by PRL2010. The hu-
man HT29 cell line was originally isolated from a human colonic
carcinoma, and it is commonly considered a valid human colonic
mucosa model for study of human-microbe interactions (30–32).
We therefore decided to use an HT29 monolayer as an in vitro
model to investigate the transcriptomic impact of B. bifidum
PRL2010 on these human intestinal cells. HT29 monolayers cul-
tivated at 15 days postconfluence were placed in contact with
PRL2010 cells for various lengths of time, namely, 0 h, 1 h (T1),
and 2 h (T2) to 4 h (T4), as well as with PBS for 1 h (representing
an unexposed cell monolayer control).
Microarray analysis was performed on samples of tissue for
each time point with the use of a CombiMatrix human array,
which contains 62,078 oligonucleotides representing 24,311
cDNAs. Interestingly, a change in the transcription profile oc-
curred when different times of exposure to PRL2010 cells were
used; 1,526 genes exhibited a significant change in their transcrip-
tion for all time points (691 genes were upregulated and 835 genes
were downregulated) (Fig. 2a and c). The number of genes whose
transcription exhibited significant changes when exposed to
PRL2010 cells for different lengths of time are also shown in Fig. 2a
and c. Functional classification of the up- and downregulated
PRL2010-affected human genes according to the Gene Ontology
(GO) database usingGO terms (AmiGo) is shown in Fig. 2b and d.
Notably, the majority of the host genes whose transcription was
influenced by the presence of PRL2010 cells were shown to be
involved in immune response and positive regulation of response
to stimulus, which confirmed previously published data (6). In-
terestingly, we noticed that after 4 h of treatment of HT29 with
PRL2010 (time point T4), the number of genes for each GO as-
signment was consistently higher than those of the other time
FIG 1 Effect of B. bifidum PRL2010 on cytokine production by Caco-2 cells. (a) ELISA quantification of secreted IL-6 and IL-8 following an 18-h stimulation at
a bifidobacterial-cell/Caco-2-cell ratio of 100. (b) Effect of PRL2010 on Caco-2 cells stably transfected with an NF-B/luciferase reporter vector, with or without
stimulation with IL-1 (2 ng/ml). R.L.U., relative luminescence units. Numerical results from two experiments conducted in duplicate are given as arithmetic
means
 standard deviations. The vertical lines indicate standard deviations. ***, statistically significant difference from control value (untreated Caco-2 cells)
according to an unpaired Student t test (P	 0.001).
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points assayed, thus suggesting that PRL2010 cells are most effec-
tive in modulating the transcriptome of HT29 human cell mono-
layers upon 4 h of contact. These results also reinforce what was
previously noticed for similar experiments performed on a differ-
ent type of human cell monolayer (6). In general, analysis of the
HT29monolayer transcriptome data suggests that PRL2010 elicits
a host innate immune response. This idea is supported by the
significant downregulation of several genes coding for cytokines
and cytokine receptors. Among these, we observed a decrease in
the transcription of genes specifying cytokines and a related recep-
tor belonging to the IL-10 family (33), namely, IL-20, IL-24, and
the receptor for IL-22 (Fig. 3b). For instance, IL-20 has been
shown to induce expression of proinflammatory cytokines, such
as TNF- in HaCat keratinocytes (34), and to act as a proinflam-
matory mediator in rheumatoid and experimental arthritis (35).
Furthermore, the IL-22 receptor, which is found on cells of non-
hematopoietic origin in the skin, kidney, liver, lung, and gut, al-
lows regulation of local epithelial cell responses after infection or
exposure to inflammatory stimulimediated by IL-22 (36). IL-22 is
a pleiotropic cytokine that has been shown to either enhance
maintenance of the epithelial barrier (37) or exert proinflamma-
tory/pathological properties (38) following infection. In addition,
PRL2010 was shown to downregulate transcription of the gene
specifying IL-25, a member of the IL-17 family known to be ex-
pressed in epithelial cells and involved in triggering Th2-type cy-
tokines; it is thus implied to play a role in allergy (39).
FIG 2 Venn diagram illustrating the numbers of shared and unique human genes upregulated (a) and downregulated (c) between each time point of sampling
and the corresponding GO functional categories of the upregulated human genes (b) and downregulated human genes (d). The PRL2010 cells were placed in
contact with an HT29 monolayer for different lengths of time, i.e., 1 h (T1) or 2 h (T2) to 4 h (T4); as a control, HT29 monolayer cells were incubated with PBS
for 1 h (T1 PBS). Each circle in the Venn diagram represents the number of genes upregulated (a) or downregulated (b) at different time points. The number of
genes within each GO functional category observed to be upregulated (b) or downregulated (d) for various time points is indicated on the x axis. The code for
each GO category described is provided.
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The effect of PRL2010 cells on the HT29 transcriptome also
positively affected the transcription of certain interleukin-encod-
ing genes. In particular, PRL2010 exposure induced a marked in-
crease (4-fold) in the transcription of the IL-11-encoding gene
and a modest increase (2.1-fold) in the transcription of the gene
specifying its corresponding receptor, IL11RA (Fig. 3a). Interest-
ingly, preclinical in vivo and in vitro studies have demonstrated
that IL-11 inhibits the secretion of a number of proinflammatory
cytokines, such as TNF, IL-12, IL-1, and nitric oxide, from acti-
vated macrophages as well as gamma interferon (IFN-) and
IL-12 from activated T cells (40–42).
Intestinal epithelial cells are important players in gut homeo-
stasis due to their role in regulating inflammation also through the
expression of chemokines and related receptors and the conse-
quential interactionwith circulating leukocytes (43). Chemokines
are a superfamily of chemotactic cytokines which are involved in
attraction and recruitment of leukocytes to the site of inflamma-
tion, while they also play a role in angiogenesis and carcinogenesis
(44). Our data show that the stimulation of HT29 cells with B.
bifidumPRL2010 induced significant transcriptional downregula-
tion of genes that encode several chemokines and chemokine re-
ceptors (Fig. 3b). For instance, PRL2010 was shown to downregu-
FIG 3 Identification of themost statistically significantly differentially expressedHomo sapiens (Hs) genes upon treatmentwith PRL2010 bymicroarray analyses.
(a) Upregulated human genes; (b) downregulated human genes. Each row represents a separate transcript, and each column represents a separate sample (T1,
T2, and T4). The color legend is at the top of the microarray plot; green indicates increased transcription levels compared to those of the reference sample.
Turroni et al.
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late the genes coding for chemokines of the CXC family, such as
CXCL2 and CXCL3. These two chemokines (also known as
growth-related oncogenes GRO2 and GRO3) have been found to
be overexpressed in colorectal carcinoma compared to healthy
tissue (45). CXCL2 and CXCL3 are in fact considered biomarkers
for the angiogenesis of tumors, and their expression in HT29 was
demonstrated to be triggered by proinflammatory stimulation
(44). Nevertheless, in vivo studies of humans involving PRL2010
should be performed in order to further investigate the relevance
and importance of these findings. Furthermore, PRL2010 was
shown to markedly downregulate the transcription of the
CXCL16-encoding gene. Interestingly, CXCL16 is considered a
marker for inflammation due to its perceived role in the develop-
ment of inflammatory bowel disease (46). In addition, expression
of CXCL16 has been found to be upregulated in several types of
primary and metastatic cancer tissue and cancer cell lines and has
been proposed as a prognosticmarker for colorectal cancer (CRC)
(47).
The chemokine whose corresponding gene was most strongly
repressed by PRL2010 exposure was CCL22 (Fig. 3b). Also known
as macrophage-derived chemokine (MDC), CCL22 has been
found to be expressed in the small intestine (48) and was demon-
strated to be a potent chemoattractant of immune cells, in partic-
ular, immature dendritic cells (DCs). High levels of CCL22 have
been found following stimulation with proinflammatory stimuli
like TNF-, IL-1, IFN-, and lipopolysaccharide (LPS) (49, 50)
and in specimens of inflamed mucosae (51).
Finally, PRL2010 exposure induced a strong increase (5-fold)
in the transcription of the gene encoding CCL19, which is a
chemokine that attracts both DCs and T lymphocytes. CCL19
expression has been found to be enhanced during inflammation
by cells properly associated with the immune system (e.g., DCs)
(52). Nonetheless, it is noteworthy that CCL19 has been shown to
serve as a potential immune stimulator that can reduce tumor
burden in a model of advanced lung cancer (53). Taken together,
these results indicate an opposing effect of PRL2010 exposure on
the production of certain chemokines, such as CCL22 andCCL19,
with apparently similar functions, which supports the idea that
PRL2010 has a balanced effect on chemokine-mediated immune
functions.
It has been well established that the intestinal mucosa plays a
pivotal role in rejecting pathogens, dampening inflammatory re-
sponses, and discriminating between “friends and foes,” thus or-
chestrating tolerance to or mounting immune responses against
commensals or pathogens, respectively. Consequently, the overall
ability of B. bifidum PRL2010 to modulate cytokine/chemokine
gene expression in HT29 cells suggests that this bacterium can
actively exert tolerogenic and potentially immunomodulatory ef-
fects.
The ability of PRL2010 tomodulate inflammatory responses is
corroborated by the observed transcriptional downregulation of
the genes encoding various heat shock proteins (HSPs) of the host
(Fig. 3b). Although best described as protein chaperones during
cellular stress (54), recent evidence suggests that HSPs are also
important for activation of the innate immune response (55). Re-
lease of inducible HSPs from necrotic cells is interpreted as a dan-
ger signal by antigen-presenting cells and as a result causes cellular
activation and cytokine production (56, 57). Furthermore, pep-
tides binding to HSPs act as sources of antigen and affect the
maturation of dendritic cells (56, 58). Upregulation of HSP ex-
pression is the general response to all types of general stresses,
including infection (59). Consequently, downregulation of HSPs
by B. bifidum PRL2010 can be interpreted as a means to affect the
host inflammatory response to pathogens. This scenario is com-
pletely different than that caused by many enteropathogens,
which have been shown to increase the levels of expression of
HSPs (60). Furthermore, according to a recent model regarding
tumor development, HSPs have been implicated in tumorigenesis
resulting from both infection and chronic inflammation (60).
Other genes involved in bacterial-host interaction are genes
encoding integral transmembrane proteins identified in tight
junctions (TJ) called cadherin and claudin (61). Cadherins and
claudins play an important role in the maintenance of cell-cell
adhesion and recognition, and we found an upregulation espe-
cially for cadherin type 1 (3.5-fold; P 	 0.0005), type 23 (3-fold;
P 	 0.0005), protocadherin 6 (2.8-fold; P 	 0.0005), claudin 25
(2.5-fold; P	 0.0005), and claudin 4 (2.3-fold; P	 0.0005) (Fig.
3a). It has previously been shown that an opposite expression
effect is observed for pathogens, as they are known to cause a
downregulation of cadherin, thereby linking it to early gastric car-
cinogenesis events (62).
Remarkably, a series of-defensin genes were also upregulated
by PRL2010. The-defensin family is one of themajor antimicro-
bial protein families that can be expressed in the large intestine,
acting against Gram-positive and Gram-negative bacteria (63),
being efficacious against Enterobacteriaceae (e.g., Escherichia coli,
Salmonella enterica serovar Typhimurium, Listeria monocyto-
genes), Streptococcus pyogenes, Staphylococcus aureus, Pseudomo-
nas aeruginosa, and Bacteroides vulgatus (64). This finding, to-
gether with the observed overexpression of genes coding for TJ
proteins, supports the notion of B. bifidum PRL2010 being an
active contributor to the strengthening of the intestinal epithe-
lium barrier as part of the innate immune response. Interestingly,
transcription of the genes encoding tetraspanin membrane pro-
teins, which are used by pathogens to cause infection (65, 66), is
downregulated following contact with PRL2010, especially for
cadherin types 6, 9, 10, and 31 (0.5-fold; P	 0.0005).
We also found transcriptional downregulation of kallikrein
genes (0.5-fold; P 	 0.0005). Many bacterial pathogens in-
terfere with the contact system (kallikrein-kinin system) in hu-
man plasma, especially with the release of proinflammatory
kinin (67). The downregulation of these genes may reflect an
anti-inflammatory activity exerted by beneficial microorgan-
isms (Fig. 3b).
The ADAM (A disintegrin and metalloproteinase) family pro-
teins represent membrane-anchored cell surface glycoproteins
thatmay have important roles asmodulators of inflammation (68,
69). Pathogens cause upregulation of expression of ADAMmem-
brane glycoproteins in epithelial cells at mucosal sites, and this
upregulationmay be instrumental in regulating localmucosal im-
mune responses, growth factor-mediated epithelial proliferation,
and tissue remodeling associated with chronic mucosal infections
(70).We found transcriptional downregulation of a small number
of ADAM genes, especially ADAMTS2 and ADAMTS8 (0.5-
fold; P	 0.0005) (Fig. 3b).
The microarray results based on HT29 cells were verified by
RT-PCR for the most significant HT29 up- or downregulated
genes. Such analyses corroborated upregulation of IL-32 and IL-9
and downregulation of IL-13, CXCL3, CXCL2, and CXCL16 in
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PRL2010-treatedHT29 cells (see Fig. S1a in the supplementalma-
terial).
Transcriptomic profile of PRL2010 colonization in the mu-
rine model. In order to substantiate the global transcription data
achieved when exposing PRL2010 to human cell lines, we ex-
tended our investigations using BALB/c mice as an in vivo host-
microbe model. Colonization and clearance of PRL2010 was
monitored during the period of bacterial administration as well as
for 1 week of posttreatment by determining viable counts of
PRL2010 cells recovered from fecal samples. Levels of PRL2010
colonization remained stable, at approximately 106 CFU/g of fecal
material during the course of the intervention period and the sub-
sequent 2 days and at around 105 CFU/g during the washout pe-
riod (Fig. 4a). After the mice were sacrificed by cervical disloca-
tion, their individual gastrointestinal tracts were removed and
used for RNA extraction. Total RNA was extracted from cecal
FIG 4 Host response upon in vivomice colonization of B. bifidum PRL2010. (s) Population numbers of B. bifidum PRL2010 organisms colonizing the intestines
of BALB/c mice upon five consecutive daily administrations of 109 CFU of PRL2010 followed by a washout period of 1 week. Each point represents the average
of the log-transformed population sizes 
 standard deviation for five mice. The days of treatment and washout are indicated on the x axis. (b) Selection of
differentially expressed murine genes upon colonization with PRL2010 as determined by transcriptome analyses. Green indicates upregulated genes and red
downregulated genes upon treatment with PRL2010 cells. (c) GO functional categories of the differentially expressed mouse genes upon PRL2010 colonization.
Numbers of genes within eachGO functional category resulting in upregulation (represented by green bars) or downregulation (indicated by red bars) according
to the different time points are indicated on the x axis. The code for each GO category described is provided.
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tissue samples and hybridized on a CombiMatrix mouse array
representing 24,667 murine cDNAs (NCBI source).
Transcriptome analysis showed that upon colonization by
PRL2010, a total of 288 murine genes were transcribed differen-
tially from those of the murine control group (Fig. 4b), which is
numerically less than those identified in the transcriptome of the
human cell monolayer. This could be explained by the fact that,
compared to experiments in human cell monolayers, in vivo trials
in amurinemodel are based on amore complex biological system
(e.g., a complete eukaryotic organism with a complex gut micro-
biota) and could ultimately be more buffered in terms of gene
expression. One hundred forty-three genes were significantly up-
regulated by more than 2-fold, while 91 genes were significantly
downregulated upon PRL2010 colonization. Functional classifi-
cation of the murine genes that were upregulated by PRL2010
mediation indicated that themajority encode proteins involved in
cellular processes and regulation, as well as in responses to stimuli
(Fig. 4b).
As with the in vitro experiments involvingHT29, the transcrip-
tomes of colonized mice depicted a clear transcriptional down-
regulation of murine HSP-encoding genes, such as those for
Hspd1, Hspa4, and Hsp40 (Fig. 4b).
Furthermore, the transcriptomes of mice colonized with
PRL2010 were shown to exhibit enhanced transcription of the
ctnNal1 and cldn10 genes, encoding catenin alpha-like 1 and clau-
din 10, respectively, which are proteins located at the tight junc-
tions (TJ) of epithelial cells. These results are in accordance with
our in vitro observations using the HT29model with regard to the
upregulation of tight junction-associated proteins. Catenins, cad-
herins, and claudins, in fact, play a key structural role in themain-
tenance of the intestinal barrier against infection with entero-
pathogens like Listeria, which are known to infect the host by
penetrating the intestinal epithelium through a paracellular route
(71).
Transcriptional analyses also provided evidence that PRL2010
increases the transcription of genes encoding antimicrobial pro-
teins such as -defensin 18 (Fig. 4b). This protein belongs to the
defensin family proteins that are expressed in neutrophils and on
mucosal surfaces, where they are thought to play key roles in in-
nate host defense (72).
Another interesting indication of the immune-modulatory
role exerted by PRL2010 in the gut is represented by the down-
regulation of the transmembrane protein tetraspanin 33. Tetras-
panins are used by intracellular pathogens as a means of entering
and replicating within human cells. Although previous investiga-
tions have focused mainly on viruses such as hepatitis C and HIV,
it has now become evident that other microorganisms may also
associate with tetraspanins, using tetraspanin-enriched microdo-
main as a gateway to infection (73).
The gene encoding kallikrein B, plasma 1 (Klkb1)was shown to
undergo transcriptional downregulation upon exposure to
PRL2010, which further reinforces the hypothesis that this micro-
organism might invoke a potential anti-inflammatory activity.
Kallikrein cleaves kininogens to release kinins, which in turn act
as inflammation mediators. Intestinal kallikrein may degrade
growth factors and peptides, whereas kinins are responsible for
capillary permeability, pain, synthesis of cytokines, and the adhe-
sionmolecule neutrophil cascade. Recent studies have shown that
kallikrein is present in intestinal goblet cells and is released into
interstitial space during inflammation (74).
Other interesting proteins mediating host inflammation are
represented by disintegrin-like and metallopeptidase (reprolysin
type) with thrombospondin type 1 motif 2 (ADAMTSL4). Nota-
bly, the transcriptomes of mice colonized by PRL2010 show a
downregulation of the genes encoding Adamts, which confirmed
what was observed with in vitro assays involvingHT29 human cell
lines (see above and Fig. S2 in the supplemental material).
Finally, microarray analysis revealed that B. bifidum PRL2010
was able to highly induce (5-fold) the expression of host-metab-
olism-related genes, such as those encoding ELOVL family mem-
ber 6, elongation of long-chain fatty acids (Elovl6). This enzyme
catalyzes the synthesis of saturated and monounsaturated fatty
acids, as well as the conversion of palmitate to stearate (75).
Interestingly, mice deficient for Elovl6 have been shown to
become obese and develop hepatosteatosis when fed a high-fat
diet, identifying Elovl6 as a promising target for the treatment of
metabolic disorders (76).
The transcription levels of the most significantly downregu-
lated murine genes as identified by DNAmicroarray experiments
were also assayed by quantitative RT-PCR. These analyses indeed
confirmed downregulation of various hsp genes, such as cspd1,
dnaj9, hspd1, and hspa4 in the PRL2010-treated animals (Fig.
S1b).
Conclusions. A large body of data pertaining to modulated
genes in B. bifidum PRL2010 upon contact with human cell lines
(6) or during colonization of animal models (12) was previously
obtained. However, very little was known about the transcrip-
tional response of the host as a consequence of the presence of
PRL2010 cells. Here, through the use of high-throughput gene
expression technology and by employing both an in vitro cell line
model and a murine model, we assayed the host gene response
triggered by B. bifidum PRL2010 cells. Comparison of transcrip-
tome changes following B. bifidum PRL2010 exposure with the
identified murine transcriptome changes upon colonization of
mice with PRL2010 cells revealed intriguing similarities with re-
gard to transcription profiles involving HSP-encoding genes and
genes involved in tight junctions, as well as Adamts-encoding
genes. Such findings involving two different models (e.g., a rather
simple HT29 model and a complete eukaryotic organism) clearly
support the possibility of a specific effect ofB. bifidumPRL2010 on
the human immune system. The data presented also confirm and
extend previous published results achieved from Caco-2 cell
monolayers. Interestingly, the overall host response scenario
driven by PRL2010 cells may be summarized as a stimulatory re-
sponse to prime the immune system, while it, at the same time,
attenuates the proinflammatory response by downregulating cer-
tain chemokines and HSPs and upregulating defensin and tight
junction genes (Fig. S2). Overall, these results suggest that
PRL2010 exerts an immunomodulatory activity as well as a rein-
forcement of the innate defense toward its host during gut colo-
nization. Future comparative studies involving B. bifidum
PRL2010 as well as other bifidobacterial strains belonging to dif-
ferent species will be carried out in order to evaluate the existence
of specific strain/species immune-modulatory activities.
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